奈拉地松双丙氨酸盐对射血分数保留的心力衰竭患者运动能力的影响:一项随机临床试验
这项2b期随机临床试验在美国、欧洲和日本76个中心纳入305例射血分数保留的心力衰竭(HFpEF)患者,按1:2:2:2:2:3随机接受奈拉地松双丙氨酸盐5、10、20、30、40 mg或安慰剂治疗20周。主要终点为6分钟步行试验距离从基线至20周的变化,各奈拉地松组均未达到临床相关的40米增加,未识别出最佳剂量,5种剂量反应模型均未显示显著的剂量反应关系(P值范围为.05至.52)。
要点
- 各奈拉地松组6分钟步行距离变化均未达临床相关的40米增加,未识别最佳剂量。
- 5种剂量反应模型均未显示显著剂量反应关系(Emax模型P=.05,线性模型P=.39)。
- 严重不良事件在奈拉地松组(26.6%)与安慰剂组(27.6%)相似。
核心结论
- 在HFpEF患者中,奈拉地松对从基线至20周运动能力变化未检测到显著的剂量反应关系。
- 鉴于这些发现,若进一步开发奈拉地松用于治疗HFpEF患者,将需要新的方法。
研究设计与样本
- 2b期随机临床试验,在美国、欧洲和日本76个中心开展。
- 纳入305例纽约心脏协会II或III级HFpEF且利钠肽水平升高的患者,入组时间为2017年5月10日至2017年12月7日,末次随访日期为2018年6月20日。
- 参与者按1:2:2:2:2:3随机接受奈拉地松5 mg(n=27)、10 mg(n=50)、20 mg(n=51)、30 mg(n=50)、40 mg(n=51)或匹配安慰剂(n=76)治疗20周。
- 261例(86%)完成试验并纳入主要分析。
主要发现
- 305例随机患者平均年龄74岁,女性160例(53%),平均6分钟步行试验距离321.5米。
- 治疗20周后,6分钟步行试验距离较基线的平均绝对变化:安慰剂组0.2米(95%CI -12.1至12.4米);奈拉地松5 mg组19.4米(95%CI -10.8至49.7米);10 mg组29.4米(95%CI 3.0至55.8米);20 mg组13.8米(95%CI -2.3至29.8米);30 mg组16.3米(95%CI -1.1至33.6米);40 mg组13.0米(95%CI -5.9至31.9米)。
- 6分钟步行试验距离变化的剂量反应关系在5种剂量反应模型中均不显著:Emax模型P=.05;二次模型P=.18;S型Emax模型1 P=.21;线性模型P=.39;S型Emax模型2 P=.52。
- 严重不良事件在奈拉地松组(61/229,26.6%)与安慰剂组(21/76,27.6%)相似。
关键数值与推荐
- 主要终点为6分钟步行试验距离从基线至20周的变化,最小临床重要差异为40米。
- 因无奈拉地松组达到临床相关的40米增加,未识别出奈拉地松的最佳剂量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Heart failure with preserved ejection fraction (HFpEF) lacks effective treatments. Based on preclinical studies, neladenoson bialanate, a first-in-class partial adenosine A1 receptor agonist, has the potential to improve several heart failure-related cardiac and noncardiac abnormalities but has not been evaluated to treat HFpEF. OBJECTIVES: To determine whether neladenoson improves exercise capacity, physical activity, cardiac biomarkers, and quality of life in patients with HFpEF and to find the optimal dose. DESIGN, SETTING, AND PARTICIPANTS: Phase 2b randomized clinical trial conducted at 76 centers in the United States, Europe, and Japan. Patients (N = 305) with New York Heart Association class II or III HFpEF with elevated natriuretic peptide levels were enrolled between May 10, 2017, and December 7, 2017 (date of final follow-up: June 20, 2018). INTERVENTIONS: Participants were randomized (1:2:2:2:2:3) to neladenoson (n = 27 [5 mg], n = 50 [10 mg], n = 51 [20 mg], n = 50 [30 mg], and n = 51 [40 mg]) or matching placebo (n = 76) for 20 weeks of treatment. MAIN OUTCOMES AND MEASURES: The primary end point was change in 6-minute walk test distance from baseline to 20 weeks (minimal clinically important difference, 40 m). Key safety measures included bradyarrhythmias and adverse events. To evaluate the effects of varying doses of neladenoson, a multiple comparison procedure with 5 modeling techniques (linear, Emax, 2 variations of sigmoidal Emax, and quadratic) was used to evaluate diverse dose-response profiles. RESULTS: Among 305 patients who were randomized (mean age, 74 years; 160 [53%] women; mean 6-minute walk test distance, 321.5 m), 261 (86%) completed the trial and were included in the primary analysis. After 20 weeks of treatment, the mean absolute changes from baseline in 6-minute walk test distance were 0.2 m (95% CI, -12.1 to 12.4 m) for the placebo group; 19.4 m (95% CI, -10.8 to 49.7 m) for the 5 mg of neladenoson group; 29.4 m (95% CI, 3.0 to 55.8 m) for 10 mg of neladenoson group; 13.8 m (95% CI, -2.3 to 29.8 m) for 20 mg of neladenoson group; 16.3 m (95% CI, -1.1 to 33.6 m) for 30 mg of neladenoson group; and 13.0 m (95% CI, -5.9 to 31.9 m) for 40 mg of neladenoson group. Because none of the neladenoson groups achieved the clinically relevant 40-m increase in 6-minute walk test distance from baseline, an optimal dose of neladenoson was not identified. There was no significant dose-response relationship for the change in 6-minute walk test distance among the 5 different dose-response models (P = .05 for Emax; P = .18 for quadratic; P = .21 for sigmoidal Emax 1; P = .39 for linear; and P = .52 for sigmoidal Emax 2). Serious adverse events were similar among the neladenoson groups (61/229 [26.6%]) and the placebo group (21/76 [27.6%]). CONCLUSIONS AND RELEVANCE: Among patients with HFpEF, there was no significant dose-response relationship detected for neladenoson with regard to the change in exercise capacity from baseline to 20 weeks. In light of these findings, novel approaches will be needed if further development of neladenoson for the treatment of patients with HFpEF is pursued. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03098979.
引用
- Shah SJ, Voors AA, McMurray JJV, et al. Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019. PMID: 31162568. doi:10.1001/jama.2019.6717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。